FDA hands a ‘break­through’ des­ig­na­tion to Seat­tle Ge­net­ics’ piv­otal-stage can­cer drug en­for­tum­ab

Seat­tle Ge­net­ics and their part­ners at Astel­las got a boost from the FDA to­day for their quest to score an ac­cel­er­at­ed ap­proval for en­for­tum­ab ve­dotin.

The agency has stamped their break­through drug des­ig­na­tion on the pro­gram, high­light­ing its po­ten­tial as the drug makes its way through a piv­otal Phase II study for metasta­t­ic urothe­lial can­cer. That’s a wel­come en­dorse­ment for Seat­tle Ge­net­ics $SGEN, which has tapped this drug as one of its top clin­i­cal prospects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER